Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024 ...Middle East

Head-to-Head Phase 3 Trial Compared to Pembrolizumab Initiated HONG KONG, Sept. 15, 2024 /PRNewswire/ -- At the 2024 European Society for Medical Oncology (ESMO) Conference, Akeso released the Phase 2 clinical results of its internally developed PD-1/VEGF bispecific antibody, ivonescimab,...

Hence then, the article about akeso published ivonescimab plus ligufalimab as first line treatment for pd l1 positive recurrent metastatic head and neck squamous cell carcinoma at esmo 2024 was published today ( Sunday 15/09/2024 - 10:12 AM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Akeso Published Ivonescimab plus Ligufalimab as First-Line Treatment for PD-L1-Positive Recurrent/Metastatic Head and Neck Squamous Cell Carcinoma at ESMO 2024 )

Also on site :

• Amy Schumer Reveals Sexual Side Effect of Alleged 'Botched Colonoscopy'
• 1963 Rock Anthem Investigated by the FBI for Dirty Lyrics 61 Years Ago Today
• Guns on the television and in Iran’s streets as Trump renews war threats